Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 79934 for:    subjects

Single-dose PK Study of Benapenem In Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03588156
Recruitment Status : Completed
First Posted : July 17, 2018
Last Update Posted : July 17, 2018
Sponsor:
Information provided by (Responsible Party):
Sihuan Pharmaceutical Holdings Group Ltd.

Brief Summary:

To design 11 dose groups within 62.5 mg ~ 4000 mg for single-dose tolerability study. A single-center, randomized, blinded, placebo-controlled, dose escalation trial design is adopted. 8 subjects each in 62.5 mg, 125 mg, 3000 mg and 4000 mg dose groups, 10 subjects each in other groups, including 2 placebo-controlled subjects. To be carried out from low-dose group to high-dose group. The next dose group can be studied only when the observation of the previous dose group is completed and it is confirmed that the drug is safely tolerated. The test should be stopped in case of serious adverse reactions, or when more subjects experience adverse reactions and have reached termination criteria of the trial, even if the maximum dose has not been reached.

Infusion time is planned to be 30 min in 62.5 mg, 125 mg and 250 mg ; two infusion time, 30 min and 60 min, in 500 mg, 1000 mg and 2000 mg groups. If subjects can tolerate 60-min infusion, the same dose group at infusion time of 30 min is added. The 3000 mg and 4000 mg dose groups only receive 60-min infusion for investigation of tolerability.


Condition or disease Intervention/treatment Phase
Healthy Subject Drug: Benapenem Drug: Placebo Phase 1

Detailed Description:

It is planned to design 11 dose groups within 62.5 mg ~ 4000 mg for single-dose tolerability study. A single-center, randomized, blinded, placebo-controlled, dose escalation trial design is adopted. There are 8 subjects each in 62.5 mg, 125 mg, 3000 mg and 4000 mg dose groups, and 10 subjects each in other groups. Each group consists of half males and half females, including 2 placebo-controlled subjects (1 male and 1 female). The trial is carried out from low-dose group to high-dose group. Each subject only receives one dose of test drug, which is dissolved in 100 mL of 0.9% NS, intravenous drip. During the trial, the adverse events of subjects should be closely followed. The next dose group can be studied only when the observation of the previous dose group is completed and it is confirmed that the drug is safely tolerated. The test should be stopped in case of serious adverse reactions, or when more subjects experience adverse reactions and have reached termination criteria of the trial, even if the maximum dose has not been reached.

In order to investigate possible effect of infusion rate on the tolerability and to ensure the safety of subjects, the infusion time is planned to be 30 min in 62.5 mg, 125 mg and 250 mg low-dose groups; two infusion time, 30 min and 60 min, in 500 mg, 1000 mg and 2000 mg groups. Under the circumstance that subjects can tolerate 60-min infusion, the same dose group at infusion time of 30 min is added to investigate the possible effect of infusion rate on the tolerability. The 3000 mg and 4000 mg dose groups only receive 60-min infusion for investigation of tolerability.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 98 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: 11 dose groups within 62.5 mg ~ 4000 mg for single-dose tolerability study to carried out from low-dose group to high-dose group
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Single-dose Tolerability Study of Benapenem for Injection in Phase I Clinical Healthy Subjects
Actual Study Start Date : March 11, 2015
Actual Primary Completion Date : September 17, 2015
Actual Study Completion Date : September 17, 2015

Arm Intervention/treatment
Experimental: Benapenem
Investigatial Product: Benapenem: 11 group : 62.5mg one dose; 125mg one dose;250mg one dose;500mg one dose 30min infusion;500mg one dose 60min infusion ;1000mg one dose 30min infusion; 1000mg one dose 60min infusion 2000mg one dose 30min infusion;2000mg one dose 60min infusion;3000mg one dose 60min infusion;4000mg one dose 60min infusion
Drug: Benapenem
Dose-escalation For 11 level dose groups A1 ~ A11(each 62.5mg/kg, 125mg/kg, 250mg/kg, 500mg/kg, 1000mg/kg 60min infusion, 1000mg/kg 30min infusion, 2000mg/kg 60 min infusion, 2000mg/kg 30min infusion, 3000mg/kg, 4000mg/kg), 10 subjects (8 for the study drug and 2 for placebo) are randomized to each dose group
Other Name: 5081

Placebo Comparator: Placebo
Placebo control 11 group : 62.5mg one dose;125mg one dose;250mg one dose;500mg one dose 30min infusion;500mg one dose 60min infusion ;1000mg one dose 30min infusion; 1000mg one dose 60min infusion 2000mg one dose 30min infusion;2000mg one dose 60min infusion;3000mg one dose 60min infusion;4000mg one dose 60min infusion
Drug: Placebo
Placebo




Primary Outcome Measures :
  1. Number of subjects with clinically significant findings in vital signs [ Time Frame: Change from Baseline at Day1, Day2, Day4 after dosing ]
    Vitals signs such as systolic and diastolic blood pressure, heart rate, and pulse rate will be measured in a semi-supine position after 5 minutes of rest.

  2. Number of subjects with clinically significant findings in laboratory parameters [ Time Frame: Change from Baseline at Day1, Day2, Day4 after dosing ]
    Hematology and clinical chemistry and Urine Routine abnormalities will be monitored

  3. Number of subjects with clinically significant 12-lead ECGs [ Time Frame: Change from Baseline at Day1, Day2, Day4 after dosing ]
    Single 12-lead ECGs will be obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTcF intervals


Secondary Outcome Measures :
  1. AUC(0-24) of Benapenem [ Time Frame: In each group: Pre dose and 0.25,0.5,0.75,1,1.5, 2, 2.5, 3, 4, 6,8,12, 24hour after dosing ]
    AUC(0-24) is the area under the curve from time 0 to 24 hour

  2. Maximum observed plasma concentration (Cmax) of Benepenem [ Time Frame: In each group: Pre dose and 0.25,0.5,0.75,1,1.5, 2, 2.5, 3, 4, 6,8,12, 24hour after dosing ]
  3. Time to maximum observed plasma concentration (tmax) of Benapenem [ Time Frame: In each group: Pre dose and 0.25,0.5,0.75,1,1.5, 2, 2.5, 3, 4, 6,8,12, 24hour after dosing ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 1) Male or female healthy subjects, aged 18~45;
  • 2) Body weight ≥ 50 kg and body mass index 19.0~24.0 kg/m2;
  • 3) Prior to the test, physical examination, blood routine, urine routine, liver and kidney functions, and related examinations normal, or mild abnormalities in indicators while without clinical significance as indicated by the investigator;
  • 4)Normal or mild abnormalities without clinical significance in the standard 12-lead ECG;
  • 5)Signing informed consent form

Exclusion Criteria:

  • 1) Regular smoking, alcohol abuse, and drug abuse;
  • 2)Use of drugs known damage to an organ within three months;
  • 3)History of specific allergies, or history of drug allergy, especially those allergic to lactams and excipients of test drug;
  • 4)Febrile illnesses within three days before the screening;
  • 5)Patients with mental illness or psychotic disorder in the past;
  • 6)Past mental and nervous system diseases (epilepsy, stroke, cerebrovascular disorder, etc.), gastrointestinal disorder (such as stomach ulcers, gastritis, etc.) or disorder of other systems (such as cardiovascular, respiratory, hematological, or endocrine system, etc.) diseases or medical history.
  • 7)Habitually taking any medication, including traditional Chinese medicine;
  • 8)Having taken any medication that may affect test results within two weeks before the screening, such as antibiotics, NSAIDs, aluminum- or magnesium-containing antacids, diuretics, anticoagulants, central nervous system depressants, and any drug that may affect the drug absorption;
  • 9)Having participated in other investigational drug trial in the preceding three months;
  • 10)Blood donation for 360 ml or more within three months before the screening;
  • 11)Heart rate < 50 bpm or > 100 bpm;
  • 12)Systolic blood pressure<90mmHg or ≥ 140mmHg, diastolic blood pressure ≥ 90 mmHg or < 60 mmHg;
  • 13)Women who are pregnant or breastfeeding, or who may be pregnant without adopting acceptable contraception, or who have a positive result in serum pregnancy test;
  • 14)Women who are planning to become pregnant within 6 months, or male subjects who are planning to make his spouse pregnant within 6 months;
  • 15)HBsAg, HCV antibody, HIV antibody, and Treponema pallidum antibody positive;
  • 16)Urine drug-of-abuse testing positive;
  • 17)Any other factor that makes the subject not suitable for the trial as indicated by the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03588156


Sponsors and Collaborators
Sihuan Pharmaceutical Holdings Group Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Yan Zhu, Doctor Peking University First Hospital

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Sihuan Pharmaceutical Holdings Group Ltd.
ClinicalTrials.gov Identifier: NCT03588156     History of Changes
Other Study ID Numbers: 5081-CPK-1001
First Posted: July 17, 2018    Key Record Dates
Last Update Posted: July 17, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: no plan to make individual participant data

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Sihuan Pharmaceutical Holdings Group Ltd.:
Healthy Subject
PK Study
Tolerability
Safety Evaluation